Before calibration, the guideline conformity of TNBC was significantly higher than other breast cancer subtypes (87.7% vs. 79.0%, 74.1%, 83.1% and 79.7%; P<0.001); however, after calibration, the Luminal type had higher guideline conformity than other subtypes, with the highest rate in Luminal A (85.9%) and followed by the Luminal B (HER2 negative) type (79.7%). This evidence concerns the gene ERBB2 and breast carcinoma.